Log in
(Ad)
Investing in 5G is old news. I discovered a company with a revolutionary new technology that could be the next Cisco. I expect their $5 stock to climb to $90 and eventually as high as $1,200 per share. A $1,000 investment could grow to as much as $240,000.

NASDAQ:ALDR - Alder Biopharmaceuticals Stock Price, Forecast & News

$18.88
0.00 (0.00 %)
(As of 10/22/2019)
Add
Compare
Today's Range
$18.88
Now: $18.88▼
$18.88
50-Day Range
$18.88
MA: $18.88▼
$18.88
52-Week Range
$8.39
Now: $18.88▼
$19.12
VolumeN/A
Average Volume5.12 million shs
Market Capitalization$1.58 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.64
Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALDR
Previous Symbol
CUSIPN/A
CIK1423824
Webhttp://www.alderbio.com/
Phone425-205-2900

Debt

Debt-to-Equity Ratio1.74
Current Ratio8.94
Quick Ratio8.94

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.62 million
Price / Sales977.10
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.61 per share
Price / Book11.73

Profitability

EPS (Most Recent Fiscal Year)($4.87)
Net Income$-296,430,000.00
Net MarginsN/A
Return on Equity-226.13%
Return on Assets-66.86%

Miscellaneous

Employees202
Outstanding Shares83,840,000
Market Cap$1.58 billion
Next Earnings DateN/A
OptionableOptionable

Receive ALDR News and Ratings via Email

Sign-up to receive the latest news and ratings for ALDR and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:ALDR Rates by TradingView

(Ad)


Located just 25 miles from Cleveland... is a supergreenhouse unlike anything we've ever seen. Listed at over 1.4 million sq ft, (the size of 9 full-sized Costco warehouses), this marijuana grow house is capable of producing over 341,000 pounds of weed/year! And very soon it will come online and could turn a tiny 60-cent pot company into the dominator in the white-hot weed market.

Alder Biopharmaceuticals (NASDAQ:ALDR) Frequently Asked Questions

What is Alder Biopharmaceuticals' stock symbol?

Alder Biopharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."

How were Alder Biopharmaceuticals' earnings last quarter?

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) released its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.05) by $0.01. View Alder Biopharmaceuticals' Earnings History.

What price target have analysts set for ALDR?

11 brokers have issued 12-month target prices for Alder Biopharmaceuticals' stock. Their forecasts range from $14.00 to $21.00. On average, they expect Alder Biopharmaceuticals' share price to reach $18.44 in the next twelve months. This suggests that the stock has a possible downside of 2.3%. View Analyst Price Targets for Alder Biopharmaceuticals.

What is the consensus analysts' recommendation for Alder Biopharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alder Biopharmaceuticals in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alder Biopharmaceuticals.

What are Wall Street analysts saying about Alder Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Alder Biopharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (10/15/2019)
  • 2. Mizuho analysts commented, "We maintain our Neutral rating on the shares as we see limited catalysts for the shares prior to FDA approval; financing overhang as well as risks associated with commercial launch." (5/3/2019)
  • 3. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating and $14 PT on ALDR. Today (5/2), Alder reported 1Q19 earnings, including cash and STI, of $498.5M. With the BLA submission of eptinezumab (epti’) accepted by the FDA and with a PDUFA date set for February 2020, the company expects to launch the drug by early next year (1Q20), and we believe its cash on hand will enable it to fund building out a right-sized" neurology/headache-specialist focused sales force, as well as other launch prep this year; it started with the recent hiring of a chief commercial officer." (5/2/2019)

Has Alder Biopharmaceuticals been receiving favorable news coverage?

News coverage about ALDR stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alder Biopharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Alder Biopharmaceuticals.

Who are some of Alder Biopharmaceuticals' key competitors?

What other stocks do shareholders of Alder Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alder Biopharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Celgene (CELG), Celator Pharmaceuticals (CPXX), Micron Technology (MU), Alibaba Group (BABA), Synergy Pharmaceuticals (SGYP), Celldex Therapeutics (CLDX), Exelixis (EXEL) and Sarepta Therapeutics (SRPT).

Who are Alder Biopharmaceuticals' key executives?

Alder Biopharmaceuticals' management team includes the folowing people:
  • Dr. John A. Latham, Co-Founder & Chief Scientific Officer (Age 59)
  • Mr. Larry K. Benedict, Principal Accounting Officer & Exec. VP (Age 58)
  • Dr. Jeffrey T. L. Smith, Managing Director of Alder Biopharmaceuticals Limited (Age 59)
  • Mr. Robert W. Azelby, Pres, CEO & Director (Age 51)
  • Mr. Carlos Campoy, Chief Financial Officer

How do I buy shares of Alder Biopharmaceuticals?

Shares of ALDR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Alder Biopharmaceuticals' stock price today?

One share of ALDR stock can currently be purchased for approximately $18.88.

How big of a company is Alder Biopharmaceuticals?

Alder Biopharmaceuticals has a market capitalization of $1.58 billion and generates $1.62 million in revenue each year. The biopharmaceutical company earns $-296,430,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis. Alder Biopharmaceuticals employs 202 workers across the globe.View Additional Information About Alder Biopharmaceuticals.

What is Alder Biopharmaceuticals' official website?

The official website for Alder Biopharmaceuticals is http://www.alderbio.com/.

How can I contact Alder Biopharmaceuticals?

Alder Biopharmaceuticals' mailing address is 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA, 98011. The biopharmaceutical company can be reached via phone at 425-205-2900 or via email at [email protected]


MarketBeat Community Rating for Alder Biopharmaceuticals (NASDAQ ALDR)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  402 (Vote Outperform)
Underperform Votes:  332 (Vote Underperform)
Total Votes:  734
MarketBeat's community ratings are surveys of what our community members think about Alder Biopharmaceuticals and other stocks. Vote "Outperform" if you believe ALDR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2020 by MarketBeat.com Staff

Featured Article: Forex
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel